Right prescription

A series of menacing appraisals have attempted to cloud the Supreme Court's rejection of Novartis's patent application for Glivec: big pharma will begin cutting investments in India, the spirit of innovation will shrink, the introduction of new drugs will slacken, and patients will take a big hit. 

Read Full Story>>